Home/Filings/4/0000899243-22-030690
4//SEC Filing

Huang James 4

Accession 0000899243-22-030690

CIK 0000895051other

Filed

Sep 7, 8:00 PM ET

Accepted

Sep 8, 6:51 PM ET

Size

10.6 KB

Accession

0000899243-22-030690

Insider Transaction Report

Form 4
Period: 2022-09-06
Huang James
Director
Transactions
  • Purchase

    Common Stock

    2022-09-07$4.00/sh+3,111$12,433338,217 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2022-09-06$3.89/sh+19,162$74,601335,106 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2022-09-08$4.28/sh+33,300$142,627371,517 total(indirect: See Footnote)
Holdings
  • Common Stock

    191
Footnotes (4)
  • [F1]The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.80 to $4.00. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • [F2]Represents securities held by Panacea Opportunity Fund I, L.P., over which the reporting person may be deemed to indirectly share beneficial ownership. The reporting person disclaims such beneficial ownership except to the extent of his pecuniary interest therein, if any.
  • [F3]The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.9401 to $4.00. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • [F4]The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $4.115 to $4.40. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Issuer

CASI Pharmaceuticals, Inc.

CIK 0000895051

Entity typeother

Related Parties

1
  • filerCIK 0001573160

Filing Metadata

Form type
4
Filed
Sep 7, 8:00 PM ET
Accepted
Sep 8, 6:51 PM ET
Size
10.6 KB